responses (3) . In addition, chemokines and their receptors appeared to associate with particular types of immune responses, allowing for collective recruitment and interaction of several leukocyte types. A good example is the eotaxin receptor CCR3, which is expressed by multiple parasite/allergy-associated leukocytes, including eosinophils, basophils, mast cells, and Th2 cells. Likewise CXCR5 is expressed by T follicular helper (Tfh) cells and B cells and facilitates germinal center reactions. The identification and characterization of chemokines and their receptors explained, to a large degree, how the immune system was organized and how immune cells were recruited to and interacted within specific tissues.
T cells that enter nonlymphoid tissues provide front-line protection against pathogens; however, in autoimmune disease and allergy, their role is more sinister. It was therefore important to understand the nature of the T cells that actually enter inflammatory sites, as this might be informative of the type of immune responses that develop in response to invasion and in association with autoimmune disease (Th1, Th2, etc.). Prior to 1990, immunologists had assumed that most lymphocytes randomly recirculated throughout the body. Studies then emerged demonstrating that naive T cells migrated preferentially through lymph nodes via high endothelial venules (HEV), whereas memory/ effector (CD45RO + ) T cells migrated to peripheral tissues, such as skin (4, 5) . At this time, the precise nature of the T cells that traffic to inflammatory lesions received little attention.
In the 1990s, the discovery of numerous chemokine receptors provided new T cell markers, including CCR5 and CXCR3, which bound the so-called "inflammatory" chemokines, RANTES (CCL5) and IP-10 (CXCL10), respectively. At LeukoSite Inc., Boston, we pioneered methods for developing mAbs to chemokine receptors, and these mAbs proved valuable for characterizing chemokine receptor biology. For instance, use of these antibodies revealed that CCR5 and CXCR3 preferentially mark Th1 cells rather than Th2 cells (3) . The results of these and other studies led to the notion that certain chemokines and their receptors were intimately associated with certain types of inflammatory responses, whereas others were associated with constitutive homing by naive as well as a subset of memory T cells through lymph nodes. In support of this concept, CXCR4 and CCR7 proved to be receptors for lymph node homing by T cells, whereas CCR5, CXCR3, and later CCR6 were determined to mark subsets of effector/ memory T cells (6) . Prior to the 1990s, genetic analyses indicated that many autoimmune diseases are driven by T cell responses; however, the identity of the pathogenic T cell populations responsible for dysfunctional autoimmune responses remained unclear. Some 20 years ago, the discovery of numerous chemokines and their receptors along with the development of specific mAbs to these provided a distinct advance. These new tools revealed a remarkable dichotomy and disclosed that some chemokine receptors guided the constitutive migration of T cells through lymphoid tissues, whereas others, such as CCR5 and CXCR3, guided effector and memory T cell migration to inflammatory lesions. These T cell markers enabled a new understanding of immune responses and the types of T cells involved in different inflammatory reactions. jci. + T cells are an effector population associated with IFN-γ production (3), although CXCR3 can also be expressed by Th17 T cells. This suggests that IFN-γ or IL-17 is associated with the abundance of CCR5 + CXCR3 + T cells in the arthritic joint and so contributes to disease pathogenesis. Interestingly, polymorphisms within the gene encoding IFN-γ have been linked to human RA (9).
Chemokine receptors define T cell subsets

Targeting CCR5 and CXCR3 in inflammatory disease
The results of our 1998 study (7) suggested that chemokine or receptor inhibition could be an effective treatment for inflammatory diseases such as RA. In animal models of inflammatory arthritis and the experimental autoimmune encephalomyelitis (EAE) of novel inhibitors to chemokine receptors with potential to limit inflammation in autoimmune and allergic diseases, such as rheumatoid arthritis (RA), asthma, inflammatory bowel disease (IBD), multiple sclerosis (MS), and others. One of the striking results from our 1998 study published in the JCI (7) was the revelation that CXCR3 and CCR5 marked a relatively small subset of T cells in blood, but were present on the vast majority of T cells in synovial fluid or synovium from patients with RA. This striking discrepancy indicated that there was a strong and highly selective recruitment of T cells from blood to the sites of this inflammatory reaction. Furthermore, our results implied that these CXCR3 ment component C5a, results in a striking disease inhibition (11) , and trials are currently under way to evaluate the efficacy of an anti-C5aR drug in human RA. These RA models suggest that development of rheumatoid factor or citrullinated peptide antibodies might activate the complement cascade that then attracts tissue-damaging C5aR + leukocytes, such as neutrophils and activated macrophages, to the joints. Activated macrophages produce TNF or IL-6 (12), which in turn mediate synovial inflammation (Figure 1) . The chemokine ligands of CCR5 or CXCR3 are then induced by inflammatory cytokines such TNF and IFN-γ. Perhaps T cells in the joint then exacerbate disease through production of inflammatory cytokines, particularly IL-17 and IFN-γ. Of course, the genetic element that implicates T cell involvement in human RA could relate entirely to another arm of the T cell response, such as T cell help for B cells that produce pathogenic autoantibodies (Figure 1 ). Regarding other inflammatory diseases, effector T cells actually do appear to drive pathogenesis. In psoriasis, agents that block the Th17 cytokine IL-17 have been highly promising in human clinical trials. Th17 cells are marked by the chemokine receptor CCR6, which likely facilitates Th17 cell migration to the skin, although CXCR3 probably also plays a role.
